Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.33

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $20.3333.

A number of research analysts have recently weighed in on ENTA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th. Westpark Capital upped their price target on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $14.00 to $20.00 in a research report on Wednesday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Friday, January 9th. Finally, JPMorgan Chase & Co. initiated coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They set an “overweight” rating and a $17.00 price target on the stock.

Enanta Pharmaceuticals Stock Down 1.0%

Shares of ENTA stock opened at $12.49 on Friday. The firm has a market cap of $360.46 million, a price-to-earnings ratio of -3.26 and a beta of 0.95. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15. The stock has a 50-day moving average price of $14.07 and a 200 day moving average price of $10.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The company had revenue of $15.13 million for the quarter, compared to analyst estimates of $15.60 million. Sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 4,743 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the transaction, the chief executive officer directly owned 858,026 shares in the company, valued at approximately $12,209,709.98. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tara Lynn Kieffer sold 2,106 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $29,968.38. Following the sale, the insider owned 30,620 shares in the company, valued at approximately $435,722.60. This represents a 6.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,961 shares of company stock worth $170,149 in the last 90 days. Company insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its position in shares of Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,779 shares during the period. Quarry LP purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at about $81,000. Wealth Enhancement Advisory Services LLC bought a new stake in Enanta Pharmaceuticals during the second quarter worth $88,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Enanta Pharmaceuticals by 103.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 4,454 shares during the period. Finally, AlphaQuest LLC raised its position in Enanta Pharmaceuticals by 18.1% in the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 1,562 shares during the period. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.